Search Results 761-770 of 16289 for monoclonal antibody

1. Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia - Mayo Clinic

   Participation eligibility · Chemotherapy < 21 days prior to first administration of study treatment and/or monoclonal antibody < 6 weeks prior to first ...

2. Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine - Mayo Clinic

   Receipt of any monoclonal antibody treatment (within or outside a clinical trial) within 6 months before screening. Previously dosed with ALD403 or any ...

3. Tumors And Masses Clinical Trials - Mayo Clinic Research

   ... Monoclonal Antibodies Scottsdale/Phoenix, AZ. The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given ...

4. An Extension Study for Long Term Assessment of LY2951742 in Patients with Chronic Cluster Headaches - Mayo Clinic

   Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins; History or presence of other medical illness that indicates a ...

5. Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

   Pertuzumab, an anti-HER2 humanized monoclonal antibody ... In this respect, anti-ErbB2 monoclonal antibody 4D5 specifically inhibits the growth of tumor cells ...

6. Publications - David Dingli, M.D., Ph.D. - Mayo Clinic

   Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia 2022 Mar; 36 (3):873-876 ...

7. A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment - Mayo Clinic

   ... monoclonal antibodies): 2 weeks; Immune-checkpoint inhibitors (i.e., anti-PD-1, anti-PD-L1, or anti-CTLA-4): 4 weeks; Other monoclonal antibodies, antibody ...

8. Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors - Mayo Clinic

   ... monoclonal antibodies): 2 weeks. Immune-checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, or anti-CTLA-4), monoclonal antibodies, antibody-drug conjugates ...

9. Treating Highly Sensitized Patients on the Kidney Transplant Waiting List by Depleting Their B-cells Using Chimeric Antigen Receptor T Cells (CAR-T) - Mayo Clinic

   Any patients who received a desensitization therapy including any monoclonal antibodies, plasmapheresis, and/or splenectomy; Inability to understand and sign ...

10. Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies - Mayo Clinic

    Known intolerance to CD20 monoclonal antibody therapy. History of primary central nervous system (CNS) lymphoma or CNS neoplastic disease. Platelet count ...